Wallace Form 3: BridgeBio Oncology CEO Discloses 657,790 Stock Options

Rhea-AI Filing Summary

Wallace Eli M. filed an initial Form 3 reporting his beneficial ownership in BridgeBio Oncology Therapeutics, Inc. (Ticker: BBOT). The filing shows two stock options: one for 620,618 shares of common stock exercisable beginning 07/22/2034 at an exercise price of $4.17, and one for 37,172 shares exercisable beginning 04/02/2035 at $7.88. The options vest monthly in 1/48th installments beginning May 1, 2024 and April 4, 2025 respectively, subject to continued service. The Form 3 indicates Wallace is both Chief Executive Officer and a Director. The filing was signed by an attorney-in-fact on 08/18/2025 and includes a Power of Attorney exhibit.

Positive

• Clear disclosure of option amounts, exercise prices, exercisable dates, and vesting schedules
• Alignment with shareholders implied by time-based vesting tied to continued service

Negative

• Potential future dilution of 657,790 shares underlying the reported options if exercised

Insights

Corporate Governance Expert

TL;DR Initial disclosure shows executive equity compensation via time-based stock options with multi-year exercise windows.

The Form 3 is a routine Section 16 disclosure reporting Mr. Wallace's option grants as CEO and director. The material facts are the sizes, exercise prices, exercisable dates, and documented monthly vesting in 1/48th increments tied to continued service. These are standard long-term incentives aligning management with shareholder value over a multi-year period. No cash transactions, sales, or other derivative types are disclosed.

Securities Analyst

TL;DR Filing documents sizeable option holdings but contains no immediate market-moving transfers or sales.

This Form 3 discloses two option awards totaling 657,790 underlying shares with exercise prices of $4.17 and $7.88 and long-dated exercisability. The disclosure is informational for monitoring potential future dilution once options vest and are exercised, but it does not report exercised or sold securities now. The absence of non-derivative common stock holdings or sales limits current market impact.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Wallace Eli M.

(Last) (First) (Middle)

BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.

256 EAST GRAND AVENUE, SUITE 104

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/11/2025

3. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	07/22/2034	Common Stock	620,618	$4.17	D
Stock Option (Right to Buy)	(2)	04/02/2035	Common Stock	37,172	$7.88	D

Explanation of Responses:

1. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of May 1, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date.

2. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of April 4, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Aaron Chan, Attorney-in-Fact	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 3 for BBOT?

Wallace Eli M., identified as Chief Executive Officer and Director, filed the Form 3 reporting beneficial ownership in BridgeBio Oncology Therapeutics (BBOT).

What securities are reported on this Form 3?

Two stock options are reported: 620,618 shares exercisable 07/22/2034 at $4.17, and 37,172 shares exercisable 04/02/2035 at $7.88.

How do the options vest?

Each option vests in monthly installments of 1/48th of the shares, beginning May 1, 2024 for the first option and April 4, 2025 for the second, subject to continued service.

Does the Form 3 show any exercised or sold shares?

No. The filing only reports derivative securities (stock options) and does not report any exercised or sold common shares.

When was the Form 3 signed?

The document shows a signature by an attorney-in-fact, /s/ Aaron Chan, dated 08/18/2025.